Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 101 of 101 results for kidney cancer

  1. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA900

  2. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  3. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    disease, hypertension, diabetes, coronary heart disease, chronic kidney disease, cancer, cerebral vascular disease,...

    Research recommendation
    Published
    9 March 2022

  4. Impact of pharmacist involvement in enhanced recovery pathways in improving patient care in those undergoing lower gastrointestinal surgery

    collaboratively between the Department of Health, NHS Improvement and the National Cancer Action Plan. The aim of this project is to...

    Shared learning
    Last updated
    17 January 2017

  5. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

    Interventional procedures guidance
    Published
    26 June 2015
    View recommendations

    Sections for IPG524

  6. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE2

  7. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (HTE1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE1

  8. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

    Medtech innovation briefing
    Last updated
    9 June 2023

  9. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    Evidence-based recommendations on voxelotor (Oxbryta) for haemolytic anaemia caused by sickle cell disease in people 12 years and over.

    Technology appraisal guidance
    Published
    12 June 2024
    View recommendations

    Sections for TA981

  10. People at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.

    News
    Last updated
    23 January 2024

  11. New NICE quality standard identifies improvements in UTI diagnosis for women

    Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms.

    News
    Last updated
    22 January 2024